Claire M. Pfeffer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Claire M. Pfeffer has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Lauren E. Gartenhaus
Purdue University West Lafayette 2 West Lafayette, IN
49 shared publications - Nadia Atallah Lanman
Purdue Institute for Cancer Research, Purdue University, West Lafayette, United States of America
49 shared publications - Sagar M. Utturkar
Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN 47906, USA
49 shared publications - Annaleigh Benton
Department of Biological Sciences, Purdue University, West Lafayette, Indiana
48 shared publications - Ant Murphy
Purdue University
48 shared publications - Bozhi Liu
Department of Biological Sciences, Purdue University, West Lafayette, Indiana
48 shared publications
Latest Publications
- 4 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC
Pancreatic ductal adenocarcinoma (PDAC) stands to become the second most deadly cancer by 2030. Mutations in the small GTPase, KRAS, occur in over 90% of PDAC patients and drive signaling plasticity through phosphorylation cascades. Protein phosphatases are master regulators of signal transduction, yet the contribution of phosphatase dysregulation to mutant KRAS phenotypes is poorly understood. Protein phosphatase 2A (PP2A) inhibits KRAS effectors, placing this family of enzymes as key regulators of PDAC signaling. However, we previously demonstrated that pharmacological activation of PP2A elicits heterogeneous responses in PDAC cells, with some cell lines displaying augmented oncogenic signaling despite increased phosphatase activity. Here, we determined the impact of the specific PP2A subunit, B56a, on PDAC phenotypes using both genetic and pharmacological activation strategies in human PDAC cell lines and genetic mouse models. We demonstrate that B56a knockout reduces PDAC proliferation while exogenous expression exacerbates proliferative phenotypes. This increase in proliferation predominately occurs through epidermal growth factor receptor (EGFR), a critical signaling node associated with poor patient outcome. The activation of EGFR by PP2A-B56a is mediated through increased expression and processing of EGFR ligands, such as amphiregulin. In vivo, the genetic loss of Cip2a, an endogenous PP2A inhibitor, significantly increases EGFR activation and decreases overall survival. Finally, pharmacological activation of PP2A leads to increased EGFR signaling in tumors; however, EGFR inhibition mitigates this signaling and significantly decreases tumor growth compared to single-agent treatment alone. Together, these studies implicate a previously undescribed non-canonical role for PP2A-B56a in EGFR signaling that contributes to PDAC progression.
- 4 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC
Pancreatic ductal adenocarcinoma (PDAC) stands to become the second most deadly cancer by 2030. Mutations in the small GTPase, KRAS, occur in over 90% of PDAC patients and drive signaling plasticity through phosphorylation cascades. Protein phosphatases are master regulators of signal transduction, yet the contribution of phosphatase dysregulation to mutant KRAS phenotypes is poorly understood. Protein phosphatase 2A (PP2A) inhibits KRAS effectors, placing this family of enzymes as key regulators of PDAC signaling. However, we previously demonstrated that pharmacological activation of PP2A elicits heterogeneous responses in PDAC cells, with some cell lines displaying augmented oncogenic signaling despite increased phosphatase activity. Here, we determined the impact of the specific PP2A subunit, B56a, on PDAC phenotypes using both genetic and pharmacological activation strategies in human PDAC cell lines and genetic mouse models. We demonstrate that B56a knockout reduces PDAC proliferation while exogenous expression exacerbates proliferative phenotypes. This increase in proliferation predominately occurs through epidermal growth factor receptor (EGFR), a critical signaling node associated with poor patient outcome. The activation of EGFR by PP2A-B56a is mediated through increased expression and processing of EGFR ligands, such as amphiregulin. In vivo, the genetic loss of Cip2a, an endogenous PP2A inhibitor, significantly increases EGFR activation and decreases overall survival. Finally, pharmacological activation of PP2A leads to increased EGFR signaling in tumors; however, EGFR inhibition mitigates this signaling and significantly decreases tumor growth compared to single-agent treatment alone. Together, these studies implicate a previously undescribed non-canonical role for PP2A-B56a in EGFR signaling that contributes to PDAC progression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from miR-497 Target Gene Regulatory Network in Angiosarcoma
Supplementary data information and methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from miR-497 Target Gene Regulatory Network in Angiosarcoma
Supplementary data information and methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Gene Ontology analysis of miR-497 downregulated genes in ADC106 cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Gene Ontology analysis of miR-497 downregulated genes in ADC106 cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Promoter methylation and Kaplan-Meier survival plot of miR-497 expression in sarcomas.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Promoter methylation and Kaplan-Meier survival plot of miR-497 expression in sarcomas.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from miR-497 Target Gene Regulatory Network in Angiosarcoma
MiR-497 family predicted target genes significantly downregulated with miR-497 mimic.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from miR-497 Target Gene Regulatory Network in Angiosarcoma
MiR-497 family predicted target genes significantly downregulated with miR-497 mimic.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from miR-497 Target Gene Regulatory Network in Angiosarcoma
MicroRNA target gene enrichment in miR-497 mimic transfected cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from miR-497 Target Gene Regulatory Network in Angiosarcoma
MicroRNA target gene enrichment in miR-497 mimic transfected cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Validation of miR-497 target genes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Validation of miR-497 target genes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from miR-497 Target Gene Regulatory Network in Angiosarcoma
MiR-497 expression in SVR allografts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from miR-497 Target Gene Regulatory Network in Angiosarcoma
MiR-497 expression in SVR allografts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Gene ontology analysis of common miR-497 mimic downregulated genes and upregulated genes in ADcKO tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Gene ontology analysis of common miR-497 mimic downregulated genes and upregulated genes in ADcKO tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Genetic depletion of VAT1 inhibits cell migration.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from miR-497 Target Gene Regulatory Network in Angiosarcoma
Genetic depletion of VAT1 inhibits cell migration.